Superior Efficacy of Letrozole Versus Tamoxifen as First-Line Therapy for Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Study of the International Letrozole Breast Cancer Group

Henning T. Mouridsen, Mikhail Gershanovich, Yan Sun, +17

Journal of Clinical Oncology

Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study

W. Eiermann, Stefan Paepke, Justus Appfelstaedt, +10

Annals of Oncology

Surgical OncologyBreast OncologyPreoperative TreatmentMedicineCancer Management +5

Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer

M. Gershanovich, H.A. Chaudri, Diogo Ayres‐de‐Campos, +11

Annals of Oncology

Advanced Breast CancerBreast OncologyOncologyMedicineAromatase +9

Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women.

T.R. Jeffry Evans, E. Di Salle, G. Ornati, +4

PubMed

GynecologyPharmacotherapyReproductive EndocrinologyTransient EosinophiliaSteroid Metabolism +16

Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer

G Brufman, E Colajori, N. Ghilezan, +5

Annals of Oncology

Metastatic Breast CancerOncologyBreast OncologyMedicineCancer Management +6

Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis

Riccardo Saccardi, Alan Tyndall, Gerry Coghlan, +16

Bone Marrow Transplantation

TransplantationAutoimmune DiseaseMarrow TransplantationStem Cell TransplantationImmunology +9

Phase 1 study of carboplatin in patients with advanced cancer, intermittent intravenous bolus, and 24-hour infusion.

Serge Leyvraz, T Ohnuma, M. Lassus, +1

Journal of Clinical Oncology

Cancer ManagementPharmacotherapyMyeloid NeoplasiaHematological MalignancyThrombosis +16

Phase I-II study of high-dose epirubicin in advanced non-small-cell lung cancer.

Ronald Feld, Ryszard Wierzbicki, P L Walde, +5

Journal of Clinical Oncology

Phase I study of the novel distamycin derivative tallimustine (FCE 24517)

Cristiana Sessa, Olivia Pagani, Maria Grazia Zurlo, +6

Annals of Oncology

Medicinal ChemistryFce 24517Pharmaceutical ScienceBiochemistryMedicine +10

Menogaril: a new anthracycline agent entering clinical trials

J. Patrick McGovren, Kenneth G. Nelson, M. Lassus, +3

Investigational New Drugs

New Anthracycline AgentPharmacotherapyDrug DevelopmentMedicineDrug Discovery